前列腺特异性抗原最低值作为生存结局的独立预测因子:PROSPER随机临床试验的事后分析
该事后分析纳入905例接受恩扎卢胺治疗的非转移性去势抵抗性前列腺癌男性,按PSA下降深度分为4个互斥亚组,评估无转移生存(主要终点)和总生存(次要终点)。PSA下降≥90%且最低值<0.2 ng/mL组的无转移生存和总生存均未达到中位值,而PSA下降<50%组的无转移生存中位为22.1个月、总生存中位为40.8个月。结论认为PSA下降深度与临床结局改善存在统计学显著相关。
要点
- PSA下降<50%组无转移生存中位22.1个月,总生存中位40.8个月。
- PSA下降≥90%且最低值<0.2 ng/mL组无转移生存和总生存均未达到中位值。
- PSA下降深度越大与临床结局改善存在统计学显著相关。
核心结论
- PSA下降深度越大与临床结局改善存在统计学显著相关,提示在非转移性去势抵抗性前列腺癌中PSA水平变化与临床结局的关系此前被低估。
研究设计与样本
- PROSPER是一项国际、随机、双盲、安慰剂对照的3期试验,显示雄激素剥夺治疗联合恩扎卢胺较安慰剂显著改善无转移生存和总生存;本事后分析纳入905例接受恩扎卢胺治疗的男性。
主要发现
- PSA下降<50%、≥50%至<90%、≥90%且最低值≥0.2 ng/mL、≥90%且最低值<0.2 ng/mL组的中位无转移生存(95%CI)分别为22.1个月(14.8-未达到)、34.2个月(29.4-未达到)、36.6个月(33.4-未达到)和未达到。
- 上述4组的中位总生存(95%CI)分别为40.8个月(31.7-44.9)、54.4个月(49.0-67.0)、64.3个月(63.4-未达到)和未达到。
关键数值与推荐
- PSA下降分组:<50%(参照组);≥50%至<90%;≥90%且最低值≥0.2 ng/mL;≥90%且最低值<0.2 ng/mL。
- 中位值和95%CI采用12个月界标分析确定;风险比和P值基于非分层Cox比例分析模型。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This post hoc analysis of PROSPER evaluated the relationship between depth of PSA decline and clinical outcomes in enzalutamide-treated men with nonmetastatic castration-resistant prostate cancer. MATERIALS AND METHODS: PROSPER was an international, randomized, double-blind, placebo-controlled, phase 3 trial that demonstrated significantly improved metastasis-free survival and overall survival with androgen deprivation therapy plus enzalutamide vs placebo. A total of 905 enzalutamide-treated men were included in this post hoc analysis. Metastasis-free survival (primary endpoint) and overall survival (secondary endpoint) were evaluated for 4 mutually exclusive subgroups defined by PSA decline: <50% (reference); ≥50% to <90%; ≥90%, nadir ≥0.2 ng/mL; and ≥90%, nadir <0.2 ng/mL. Medians and 95% confidence intervals were determined using a 12-month landmark analysis; hazard ratios and P values were based on an unstratified Cox proportional analysis model. RESULTS: In enzalutamide-treated men, PSA declines of <50%, ≥50% to <90%, ≥90% with nadir ≥0.2 ng/mL, and ≥90% with nadir <0.2 ng/mL were associated with median metastasis-free survival in months (95% confidence intervals) of 22.1 (14.8-not reached), 34.2 (29.4-not reached), 36.6 (33.4-not reached), and not reached, respectively, and overall survival in months (95% confidence intervals) of 40.8 (31.7-44.9), 54.4 (49.0-67.0), 64.3 (63.4-not reached), and not reached, respectively. CONCLUSIONS: There was a statistically significant correlation between greater depth of PSA decline and improved clinical outcomes, suggesting a previously underappreciated relationship between changes in PSA levels and clinical outcomes in nonmetastatic castration-resistant prostate cancer.
引用
- Hussain M, Sternberg CN, Efstathiou E, et al. Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial. J Urol. 2023. PMID: 36756959. doi:10.1097/JU.0000000000003084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。